Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

Also called NCT02220920

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 146 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02220920
Other papers using this trial's data
  • Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus Cardiovascular diabetology, 2016-06-18 DOI, PubMed 27316668, PMC4912792 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02220920. Randomized; triple masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-07 (actual). Results posted on 2016-12-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Canagliflozin (TA-7284)
Intervention (Drug)
Placebo
Intervention (Drug)
Insulin
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02220920
Content hash
4fdacf0d5ebe63dd086078b6ec13c595f51a86631ae00e760dcf7c7836503d5e